MSI-H Clinical Trials in Beijing, Beijing Municipality
3 recruitingBeijing, Beijing Municipality, China
Showing 1–3 of 3 trials
Recruiting
Phase 2
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
MSI-H/dMMR Solid Tumors
BeiGene200 enrolled29 locationsNCT03736889
Recruiting
Phase 2
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
Gastric CancerColon CancerMSI-H+1 more
Peking University38 enrolled1 locationNCT06580574
Recruiting
Phase 2
A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy
MSI-H Solid Malignant Tumor
Shanghai Henlius Biotech108 enrolled33 locationsNCT03941574